METHODS: This systematic review and meta-analysis study involved a comprehensive search of several databases, including PubMed, ScienceDirect, SID, and Google Scholar, focusing on cross-sectional studies that examined the prevalence of Enterobius vermicularis infection in Iranian children. The identified studies were entered into the EndNote software for review. The quality of observational studies was evaluated using the STROBE checklist. The information extracted from the studies was entered into the Comprehensive Meta-analysis (CMA, Version 2) software. Heterogeneity among the studies was analyzed using the I2 test, and publication bias was assessed using the Egger test and funnel plot.
RESULTS: A total of 51 studies, with a sample size of 46,070 children, were included in the review. Using the random effects method, the overall prevalence of Enterobius vermicularis among children in Iran was determined to be 6.7% (95%CI: 5.2-8.6). The review of the factors affecting study heterogeneity and sample size indicated that as sample size increased, the prevalence of Enterobius vermicularis among children in Iran also increased (p = 0.578). Additionally, with an increase in the year of conducting the studies, the prevalence of Enterobius vermicularis among children in Iran decreased (p
OBJECTIVES: To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends.
DESIGN, SETTING, AND POPULATION: This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals.
EXPOSURE: Population-level LDL-C concentrations.
MAIN OUTCOMES AND MEASURES: Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C-attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals.
RESULTS: In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C-attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings.
CONCLUSIONS AND RELEVANCE: Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.